Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 54

Related Articles by Review for PubMed (Select 7710428)

1.
2.

Variability and impact on design of bioequivalence studies.

Van Peer A.

Basic Clin Pharmacol Toxicol. 2010 Mar;106(3):146-53. doi: 10.1111/j.1742-7843.2009.00485.x. Epub 2009 Nov 11. Review.

PMID:
20041877
3.

Evaluation of bioequivalence for highly variable drugs with scaled average bioequivalence.

Tothfalusi L, Endrenyi L, Arieta AG.

Clin Pharmacokinet. 2009;48(11):725-43. doi: 10.2165/11318040-000000000-00000. Review.

PMID:
19817502
4.

Regulatory aspects of modifications to innovator bronchodilator metered dose inhalers and development of generic substitutes.

Adams WP, Poochikian G, Taylor AS, Patel RM, Burke GP, Williams RL.

J Aerosol Med. 1994;7(2):119-34. Review.

PMID:
10147277
5.

The bioequivalence of highly variable drugs and drug products.

Midha KK, Rawson MJ, Hubbard JW.

Int J Clin Pharmacol Ther. 2005 Oct;43(10):485-98. Review.

PMID:
16240706
6.

Open questions on bioequivalence: an updated reappraisal.

Marzo A.

Curr Clin Pharmacol. 2007 May;2(2):179-89. Review.

PMID:
18690864
7.

Open questions on bioequivalence: some problems and some solutions.

Marzo A.

Pharmacol Res. 1999 Oct;40(4):357-68. Review.

PMID:
10527649
8.

Potential concerns about generic substitution: bioequivalence versus therapeutic equivalence of different amlodipine salt forms.

Meredith PA.

Curr Med Res Opin. 2009 Sep;25(9):2179-89. doi: 10.1185/03007990903116867. Review.

PMID:
19601710
9.

Veterinary drug bioequivalence determination.

Toutain PL, Koritz GD.

J Vet Pharmacol Ther. 1997 Apr;20(2):79-90. Review.

PMID:
9131533
10.

[Bioequivalence studies of pharmaceutical preparations].

Vetchý D, Frýbortová K, Rabisková M, Danecková H.

Cas Lek Cesk. 2007;146(5):431-3. Review. Czech.

PMID:
17554963
11.

Bioequivalence of racemic drugs.

Nerurkar SG, Dighe SV, Williams RL.

J Clin Pharmacol. 1992 Oct;32(10):935-43. Review.

12.

Bioequivalence requirements for generic products.

Nation RL, Sansom LN.

Pharmacol Ther. 1994 Apr-May;62(1-2):41-55. Review.

PMID:
7991647
13.

Bioequivalence assessment: a pharmaceutical industry perspective.

Godbillon J, Cardot JM, Lecaillon JB, Lefevre G, Sioufi A.

Eur J Drug Metab Pharmacokinet. 1996 Apr-Jun;21(2):153-8. Review.

PMID:
8839689
14.
15.

The new European Medicines Agency guideline on the investigation of bioequivalence.

Morais JA, Lobato Mdo R.

Basic Clin Pharmacol Toxicol. 2010 Mar;106(3):221-5. doi: 10.1111/j.1742-7843.2009.00518.x. Epub 2010 Jan 7. Review.

PMID:
20070293
16.

Bioequivalence and generic prescribing: an industrial view.

Pidgen A.

J Pharm Pharmacol. 1996 Jan;48(1):11-6. Review.

PMID:
8722487
17.

Critical considerations into the new EMA guideline on bioequivalence.

Marzo A, Fontana E.

Arzneimittelforschung. 2011;61(4):207-20. doi: 10.1055/s-0031-1296190. Review.

PMID:
21650079
18.

PhRMA perspective on population and individual bioequivalence.

Barrett JS, Batra V, Chow A, Cook J, Gould AL, Heller AH, Lo MW, Patterson SD, Smith BP, Stritar JA, Vega JM, Zariffa N.

J Clin Pharmacol. 2000 Jun;40(6):561-70. Review.

19.

Generic clozapine: a cost-saving alternative to brand name clozapine?

Tse G, Thompson D, Procyshyn RM.

Pharmacoeconomics. 2003;21(1):1-11. Review.

PMID:
12484800
20.

Bioequivalence approaches for highly variable drugs and drug products.

Haidar SH, Davit B, Chen ML, Conner D, Lee L, Li QH, Lionberger R, Makhlouf F, Patel D, Schuirmann DJ, Yu LX.

Pharm Res. 2008 Jan;25(1):237-41. Epub 2007 Sep 22. Review.

PMID:
17891552
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk